BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Has Average Price Target of $89.17 According to Brokerages

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has received a consensus rating of “Moderate Buy” from the twenty-four analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, fifteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $89.17.

BMRN has been the topic of a number of recent analyst reports. Weiss Ratings downgraded BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 18th. UBS Group set a $88.00 price target on BioMarin Pharmaceutical in a report on Wednesday, August 26th. Morgan Stanley lifted their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Royal Bank Of Canada reduced their price objective on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 7th. Finally, William Blair raised shares of BioMarin Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd.

BioMarin Pharmaceutical Trading Down 1.8%

BioMarin Pharmaceutical stock opened at $55.20 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The company has a market capitalization of $10.69 billion, a price-to-earnings ratio of 149.19, a PEG ratio of 0.40 and a beta of 0.22. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98. The company’s fifty day moving average price is $63.83 and its two-hundred day moving average price is $58.67.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, analysts forecast that BioMarin Pharmaceutical will post 4.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BMRN. Primecap Management Co. CA bought a new position in shares of BioMarin Pharmaceutical in the second quarter worth about $811,962,000. Dimensional Fund Advisors LP boosted its stake in BioMarin Pharmaceutical by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock valued at $214,804,000 after purchasing an additional 481,176 shares during the period. Geode Capital Management LLC boosted its stake in BioMarin Pharmaceutical by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 3,674,089 shares of the biotechnology company’s stock valued at $218,395,000 after purchasing an additional 131,969 shares during the period. Capital Research Global Investors grew its holdings in BioMarin Pharmaceutical by 0.4% in the 4th quarter. Capital Research Global Investors now owns 2,547,287 shares of the biotechnology company’s stock valued at $151,385,000 after buying an additional 9,691 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in BioMarin Pharmaceutical by 35.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,920,658 shares of the biotechnology company’s stock valued at $108,498,000 after buying an additional 501,591 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.